Press Release

Arrakis Therapeutics to Participate in Upcoming Investor Conferences

Waltham, MA –  March 31, 2022 –  Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that company management will participate in the following upcoming investor conferences:

Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare
Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m. ET in New York. Company management will also participate in one-on-one meetings.

21st Annual Needham Virtual Healthcare Conference
Company management will participate in one-on-one meetings on Tuesday, April 12, 2022.

About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit and engage with us on Twitter @ArrakisTx or on LinkedIn.


Media Contact:
Kathryn Morris
[email protected]

Investor Contact:
Will O’Connor
[email protected]


Back to Top